<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Charit</roleName><forename type="first">Marcus</forename><surname>Maurer</surname></persName>
							<email>marcus.maurer@charite.de</email>
							<idno type="ORCID">0000-0002-4121-481X</idno>
							<affiliation key="aff0">
								<orgName type="institution">Charit e -Universit€ atsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">M</forename><surname>Abuzakouk</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">Cleveland Clinic Abu Dhabi</orgName>
								<address>
									<settlement>Abu Dhabi</settlement>
									<country key="AE">UAE</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">F B</forename><surname>Erard</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Claude Bernard University Lyon</orgName>
								<address>
									<settlement>Lyon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">W</forename><surname>Canonica</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution">IRCCS-Humanitas Research Hospital</orgName>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution">Humanitas University</orgName>
								<address>
									<settlement>Rozzano-Milano</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">H</forename><surname>Oude Elberink</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution">University of Groningen</orgName>
								<address>
									<settlement>Groningen</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">A</forename><surname>Gim Enez-Arnau</surname></persName>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">C</forename><surname>Grattan</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Hospital del Mar</orgName>
								<orgName type="institution">Universitat Aut onoma</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">Guy&apos;s Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">K</forename><surname>Hollis</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">RTI Health Solutions</orgName>
								<address>
									<addrLine>Research Triangle Park</addrLine>
									<region>NC</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">A</forename><surname>Knulst</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution">University Medical Center Utrecht</orgName>
								<address>
									<settlement>Utrecht</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J.-P</forename><surname>Lacour</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">Universit e Nice Sophia Antipolis</orgName>
								<address>
									<settlement>Nice</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">C</forename><surname>Lynde</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">Lynderm Research</orgName>
								<address>
									<settlement>Toronto</settlement>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">A</forename><surname>Marsland</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution" key="instit1">Salford Royal Hospital</orgName>
								<orgName type="institution" key="instit2">University of Manchester</orgName>
								<address>
									<settlement>Salford</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">D</forename><surname>Mcbride</surname></persName>
							<affiliation key="aff13">
								<orgName type="institution">RTI Health Solutions</orgName>
								<address>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">A</forename><surname>Nakonechna</surname></persName>
							<affiliation key="aff14">
								<orgName type="institution">Royal Liverpool and Broadgreen University Hospitals</orgName>
								<address>
									<settlement>Liverpool</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">J</forename><surname>Ortiz De Frutos</surname></persName>
							<affiliation key="aff15">
								<orgName type="institution">Hospital</orgName>
								<address>
									<addrLine>12 Octubre</addrLine>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">C</forename><surname>Proctor</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">RTI Health Solutions</orgName>
								<address>
									<addrLine>Research Triangle Park</addrLine>
									<region>NC</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">G</forename><surname>Sussman</surname></persName>
							<affiliation key="aff16">
								<orgName type="institution">University of Toronto</orgName>
								<address>
									<settlement>Toronto</settlement>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">C</forename><surname>Sweeney</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">RTI Health Solutions</orgName>
								<address>
									<addrLine>Research Triangle Park</addrLine>
									<region>NC</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">H</forename><surname>Tian</surname></persName>
							<affiliation key="aff17">
								<orgName type="institution">Novartis Pharmaceuticals Corporation</orgName>
								<address>
									<settlement>East Hanover</settlement>
									<region>NJ</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">K</forename><surname>Weller</surname></persName>
							<idno type="ORCID">0000-0003-4437-0313</idno>
							<affiliation key="aff0">
								<orgName type="institution">Charit e -Universit€ atsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">D</forename><surname>Wolin</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">RTI Health Solutions</orgName>
								<address>
									<addrLine>Research Triangle Park</addrLine>
									<region>NC</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M.-M</forename><surname>Balp</surname></persName>
							<affiliation key="aff18">
								<orgName type="institution">Novartis Pharma AG</orgName>
								<address>
									<settlement>Basel</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MStat</roleName><forename type="first">Christina</forename><surname>Proctor</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Werner</forename><surname>Aberer</surname></persName>
						</author>
						<author>
							<affiliation key="aff19">
								<orgName type="institution">Universit€ atsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">DB45D1DBA603769EC539D43DE8B06818</idno>
					<idno type="DOI">10.1111/all.13209</idno>
					<note type="submission">Accepted: 16 May 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:08+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>angioedema</term>
					<term>economic burden</term>
					<term>observational study</term>
					<term>quality of life</term>
					<term>urticaria</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Chronic spontaneous urticaria (CSU) can be debilitating, difficult to treat, and frustrating for patients and physicians.</s><s>Real-world evidence for the burden of CSU is limited.</s><s>The objective of this study was to document disease duration, treatment history, and disease activity, as well as impact on health-related quality of life (HRQoL) and work among patients with inadequately controlled CSU, and to describe its humanistic, societal, and economic burden.</s></p><p><s>Methods: This international observational study assessed a cohort of 673 adult patients with CSU whose symptoms persisted for ≥12 months despite treatment.</s></p><p><s>Demographics, disease characteristics, and healthcare resource use in the previous 12 months were collected from medical records.</s><s>Patient-reported data on urticaria and angioedema symptoms, HRQoL, and work productivity and activity impairment were collected from a survey and a diary.</s></p><p><s>Results: Almost 50% of patients had moderate-to-severe disease activity as reported by Urticaria Activity Score.</s><s>Mean (SD) Dermatology Life Quality Index and Chronic Urticaria Quality of Life Questionnaire scores were 9.1 (6.62) and 33.6 (20.99), respectively.</s><s>Chronic spontaneous urticaria markedly interfered with sleep and daily activities.</s><s>Angioedema in the previous 12 months was reported by 66% of enrolled patients and significantly affected HRQoL.</s><s>More than 20% of patients reported ≥1 hour per week of missed work; productivity impairment was 27%.</s></p><p><s>These effects increased with increasing disease activity.</s><s>Significant healthcare resources and costs were incurred to treat CSU.</s></p><p><s>Conclusions: Chronic spontaneous urticaria has considerable humanistic and economic impacts.</s><s>Patients with greater disease activity and with angioedema experience greater HRQoL impairments.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>lence of CSU is approximately 0.5% to 1%. <ref type="bibr" target="#b21">9</ref> Until omalizumab was approved in early 2014, H 1 -antihistamines were the only approved medication for CSU and were the mainstay of symptomatic treatment.</s><s>However, over 60% of patients remain symptomatic despite treatment with second-generation H 1 -antihistamines at the licensed dose. <ref type="bibr" target="#b22">10</ref></s><s>6]<ref type="bibr" target="#b29">[17]</ref> Nevertheless, real-world research quantifying the humanistic and economic impact of diagnosed CSU is limited, and a number of unmet needs exist in this patient population, <ref type="bibr" target="#b21">9</ref> particularly among those refractory to standard treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>The ASSURE-CSU (ASSessment of the Economic and Humanistic</head><p><s>Burden of Chronic Spontaneous/Idiopathic URticaria patiEnts) study sought to improve understanding of CSU and to explore the unmet needs of patients whose disease has persisted for longer than 12 months and is inadequately controlled by standard treatment.</s><s>Specifically, the main objectives of this study were to characterize, in this population, disease duration, disease activity, and treatment history, as well as to identify and quantify the humanistic, societal, and economic burden of CSU.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">| ME TH ODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1">| Study design and participants</head><p><s>The study design has previously been described in detail. <ref type="bibr" target="#b30">18</ref></s><s>Briefly, this noninterventional, multinational, and multicenter study was conducted in Canada, France, Germany, Italy, Spain, the Netherlands, and the United Kingdom (UK).</s><s>Recruitment of 700 patients was planned.</s><s>Data collection occurred from October 2013 until May 2015, with each center recruiting over a 4-month period.</s><s>Figure <ref type="figure" target="#fig_3">S1</ref> describes the patient selection process.</s><s>Eligible patients were adults with a clinician-confirmed diagnosis of CSU <ref type="bibr" target="#b31">19</ref> who had received at least one treatment course with an H1-antihistamine and were symptomatic despite treatment. <ref type="bibr" target="#b30">18</ref></s><s>e study was reviewed and exempted by the RTI International Institutional Review Board and was reviewed and approved by the relevant national, local, and site-level ethics committees.</s><s>The study was conducted in accordance with the Declaration of Helsinki; <ref type="bibr" target="#b32">20</ref> all patients provided written informed consent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">| Study measures</head><p><s>The study included a 12-month retrospective medical record abstraction, a cross-sectional patient survey administered at enrollment, and a patient diary completed over an 8-day period after recruitment (Figure <ref type="figure" target="#fig_3">1</ref>).</s><s>Both the survey <ref type="bibr" target="#b33">[21]</ref><ref type="bibr" target="#b34">[22]</ref><ref type="bibr" target="#b35">[23]</ref><ref type="bibr" target="#b36">[24]</ref><ref type="bibr" target="#b37">[25]</ref> and the patient diary <ref type="bibr" target="#b38">[26]</ref><ref type="bibr" target="#b39">[27]</ref><ref type="bibr" target="#b40">[28]</ref> included study-specific questions and validated PRO measures (Table <ref type="table">S1</ref> in Appendix S1).</s></p><p><s>Direct and indirect costs were estimated for each country.</s><s>Direct costs included CSU-related treatments, physician visits, emergency department (ED) visits, and hospitalizations documented in medical records, as well as CSU-related alternative medicine, other out-ofpocket costs, and transportation reported in the patient survey.</s><s>Indirect costs included the cost of patient-reported workdays missed and lost productivity due to CSU.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3">| Data analysis</head><p><s>Data analyses were descriptive.</s><s>Data from all countries were pooled for all outcomes except for direct and indirect costs.</s><s>With the exception of imputation of missing start dates for therapy data, no imputation of missing data was performed, and no formal hypothesis testing was conducted.</s><s>Descriptive tables were generated overall and stratified by Urticaria Activity Score over 7 days, twice-daily assessment (UAS7) score bands.</s><s>These score bands categorize the UAS7 into four levels of disease activity: UAS7=0-6 (urticaria-free or well-controlled urticaria activity), 7-15 (mild activity), 16-27 (moderate activity), and 28-42 (severe activity). <ref type="bibr" target="#b41">29,</ref><ref type="bibr" target="#b42">30</ref></s><s>Mean values, standard deviations (SDs), medians, and ranges were computed for continuous variables; counts were collected and percentages were computed for categorical variables.</s><s>All analyses were performed using SAS version 9.3 or later (Cary, North Carolina, USA: SAS Institute, Inc.; 2011).</s></p><p><s>For the direct cost calculations, costing algorithms were used to assign 2014 unit costs from published sources in the respective country's currency to the resource utilization data. <ref type="bibr" target="#b43">31</ref></s><s>Indirect costs for workdays missed and lost productivity due to CSU were calculated by the human capital approach using each country's specific average wage and hours worked. <ref type="bibr" target="#b44">32</ref></s><s>Pooled cost calculations were not conducted.</s><s>Country costs were converted to purchasing power parity dollars (PPP$) using published methodology and sources. <ref type="bibr" target="#b45">33</ref></s><s>All cost calculations were performed using Microsoft Excel 2010.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">| RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">| Patient population</head><p><s>A total of 673 patients were enrolled in 64 recruiting centers, primarily hospital-based specialist centers (Table <ref type="table">S2</ref>    <ref type="table">S3</ref> in Appendix S3).</s><s>Most physicians reported using a combination of factors to assess CSU severity, including number, duration, and intensity of flares (58.5%) and impact on QoL (38.0%); some reported using validated PRO measures, including the UAS7 (15.9%).</s><s>Allergic rhinitis (16.5%), personal history or family history of allergic disease (14.0% and 14.1%, respectively), and asthma (11.3%) were the most frequently reported additional conditions present at enrollment; concomitant autoimmune diseases, including Hashimoto's, were not uncommon (Table <ref type="table">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">| Urticaria activity</head><p><s>The overall mean (SD) UAS7 score was 17.3 (10.49), suggesting moderate patient-reported disease activity over 7 days despite treatment.</s><s>Of the 605 people for whom a UAS7 score could be calculated, 299 (49.4%) had moderate-to-severe activity despite treatment, with mean (SD) UAS7 scores of 21.5 (3.39)   Mean (SD) total scores for the Chronic Urticaria Quality of Life Questionnaire (CU-Q 2 oL) and Dermatology Life Quality Index (DLQI) were 33.6 (20.99) and 9.1 (6.62), respectively; 41.6% of patients had a mean DLQI score of 10 or above.</s><s>The mean (SD) utility score estimate based on the generic EQ-5D-3L index was 0.714 (0.2907).</s></p><p><s>Overall, the most affected aspects of HRQoL were physical symptoms/discomfort, emotional well-being, interference with daily activities, sleep, and work performance (Figure <ref type="figure" target="#fig_1">3</ref>).</s><s>The most affected domains of the CU-Q 2 oL <ref type="bibr" target="#b35">23</ref> were pruritus (mean [SD] score, 55.2 [27.88]), sleep problems (38.3 [25.69]), and looks (35.5 [25.34]) (Fig- <ref type="figure" target="#fig_1">ure 3A</ref>).</s><s>Among the six DLQI domains, negative impact was greatest on symptoms and feelings and daily activities (3.0 [1.63] and 1.9 [1.72], respectively, of a maximum possible domain score of 6) and work and school (1.6 [0.97] of a maximum possible domain score of 3) (Figure <ref type="figure" target="#fig_1">3B</ref>).</s><s>The EQ-5D-3L domains for which patients most frequently reported moderate or extreme problems were pain/ discomfort (63.2% of patients), anxiety/depression (47.4%), and usual activities (34.2%) (Figure <ref type="figure" target="#fig_1">3C</ref>).</s><s>Chronic spontaneous urticaria also had an impact on sleep and daily activities, as shown by weekly mean (SD) scores on the interference with sleep (6.6 [5.93]) and interference with daily activities Across nearly all HRQoL domains, impact increased with increasing CSU activity.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4">| CSU-associated angioedema is a common and debilitating problem</head><p><s>According to medical records, 58.5% (394 of 673) patients were reported to have had CSU-associated angioedema, and 41.0%</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5">| CSU affects work performance and productivity</head><p><s>Of the 604 patients reporting, 341 (56.5%) indicated that they were currently employed.</s><s>Among employed patients, the mean (SD) absenteeism, presenteeism, and overall work impairment were 6.1% (17.83%), 25</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4">| DISCUSSION</head><p><s>To our knowledge, the ASSURE-CSU study is the first international analysis of the burden of CSU inadequately controlled by standard treatment.</s><s>We report novel findings for current treatment patterns, impact on HRQoL, and the economic burden to patients, healthcare systems, and society.</s><s>A key strength is the use of a patient survey and retrospective medical record review to provide  Angioedema was found to be more frequent than previously thought: Physicians reported that nearly 60% of patients with CSU experienced angioedema, and two-thirds of them had experienced it within the past 12 months.</s><s>More patients than physicians reported angioedema during this time period and reported its considerable impact on emotional well-being, fatigue, and mood.</s><s>Our findings suggest that angioedema plays a significant role in the burden of CSU, affecting every aspect of HRQoL and driving direct costs.</s><s>Further analyses of ASSURE-CSU data are ongoing to examine the misalignment between physicians' and patients' reports and to better understand the impact of angioedema.</s></p><p><s>Mean DLQI scores in this study suggest that CSU has a moderate impact on patients' HRQoL, <ref type="bibr" target="#b47">35</ref> which is greater than previously thought; further, more than 40% had DLQI scores of 10 or greater, which, in psoriasis, justifies the initiation of a biologic. <ref type="bibr" target="#b48">36</ref></s><s>In addition, HRQoL impairments correlated with disease activity, notably so in daily activity and sleep interference domains across measures.</s><s>Particularly in patients with a UAS7 of 16 or greater, overall impact of CSU on usual activities represents a significant burden to themselves and to society.</s><s>Some notable differences were observed between patient and physician reporting, potentially suggesting that patients may not always communicate their urticaria symptoms to their physicians, in turn mitigating physicians' ability to treat effectively.</s><s>Unanswered questions remain about patients' abilities to accurately identify or recall angioedema symptoms and physicians' likelihood of capturing these events in medical records.</s><s>Discrepancies also existed between physicians' and patients' reports of resources used-specifically visits to other healthcare professionals and medications, particularly alternative therapies (eg, homeopathic treatments), that the patient was using.</s><s>More research is needed to fully address these differences and provide education and resources to patients and providers alike.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ASSessment of the Economic and Humanistic Burden of Chronic</head><p><s>Spontaneous/Idiopathic URticaria patiEnts provides valuable insight into the economic burden of CSU.</s><s>To our knowledge, only a US claims database analysis, <ref type="bibr" target="#b49">37</ref> a small US single-center analysis, <ref type="bibr" target="#b50">38</ref> and a cost-effectiveness analysis in France <ref type="bibr" target="#b51">39</ref> have previously evaluated CSU-associated costs, and none is directly comparable with our study.</s><s>Although previously thought to be infrequent, CSU-related ED visits in ASSURE-CSU were reported for 14% of patients, and hospitalizations were reported for 8% of patients.</s><s>This is in contrast to Broder and colleagues' <ref type="bibr" target="#b49">37</ref>  work.</s><s>These findings are comparable with work productivity impairments in chronic urticaria <ref type="bibr" target="#b27">[15]</ref><ref type="bibr" target="#b28">[16]</ref><ref type="bibr" target="#b29">[17]</ref> and in other dermatologic conditions, including atopic dermatitis, <ref type="bibr" target="#b52">40,</ref><ref type="bibr" target="#b53">41</ref> plaque psoriasis, <ref type="bibr" target="#b54">42</ref> and severe psoriasis. <ref type="bibr" target="#b28">16,</ref><ref type="bibr" target="#b55">43,</ref><ref type="bibr" target="#b56">44</ref></s><s>e reasons for ED visits and hospitalizations may center on patient and physician awareness and education.</s><s>Depending on the healthcare system in a country, the use of this high-cost care could be due to an inaccessibility of primary-or secondary-care physicians for flare-ups and steroid prescriptions.</s><s>Alternatively, patients who have been treated in the ED before may feel that it is where CSU should be treated, or they may receive secondary gain from this visit, such as sick leave.</s><s>In certain circumstances, hospitalization may be used for observation or to manage angioedema when anaphylaxis is feared by inexperienced ED physicians or because of delays in specialist referral.</s></p><p><s>Treatment modalities reported included therapies recommended in the current guidelines during the study period.</s><s>However, patients</s></p><p><s>were not always treated along formal guideline recommendations:</s></p><p><s>For example, sedating first-generation H 1 -antihistamines, intravenous immunoglobulin, and long-term oral corticosteroids were not uncommon.</s><s>These results suggest that, at the time of study, some providers may have had insufficient resources or knowledge in treating patients with CSU.</s><s>They may have resorted to trial-and-error approaches with therapies that carry significant side-effect risks and lack efficacy evidence, 2 particularly when treating patients refractory to standard licensed therapy.</s><s>Moreover, the monoclonal antibody omalizumab was included in the urticaria treatment guidelines in   While the study used a systematic patient selection method, a similar approach was not possible for physician and center selection due to the small number of specialist units for this population.</s><s>Centers were selected to achieve variation in location, specialty, size, and type, but the resulting sample is not guaranteed to be representative of all centers and physicians treating patients with CSU.</s><s>Likewise, inclusion criteria required patients to be symptomatic despite treatment and thus, the study does not reflect the entire population of patients with CSU.</s></p><p><s>Data and information about symptoms, HRQoL, and out-ofpocket expenses collected in the patient survey may have been subject to recall bias.</s><s>The recall period for validated PROs varied from 7 days for the DLQI to 4 weeks for the AE-QoL and for the patient medical resource survey was limited to 3 months to minimize the potential for such bias.</s><s>While there was some heterogeneity across countries, results were strikingly similar particularly with respect to HRQoL.</s></p><p><s>Additional research is needed to explore patient characteristics, given that most patients in ASSURE-CSU were Caucasian and (consistent with previous findings <ref type="bibr" target="#b57">45,</ref><ref type="bibr" target="#b58">46</ref> ) female, as well as patterns relating to disease activity and duration of disease.</s><s>Because of the inherent fluctuations in CSU activity, longer or repeated assessments would help confirm the results.</s><s>The impact of CSU on work performance and productivity warrants additional evaluation.</s><s>Our findings suggest that there may be inadequate knowledge among medical staff of the appropriate workup for CSU, and there is a need to increase awareness of the economic and humanistic impact of CSU among primary-and secondary-care providers and society in general.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5">| CONCLUSIONS</head><p><s>Chronic spontaneous urticaria is a chronic, disabling disease with little previous research that is challenging to treat adequately.</s><s>The humanistic and economic burden of CSU has been underestimated.</s><s>There is considerable delay in diagnosis and specialist referral, and there is inadequate knowledge among medical staff in primary and secondary care about CSU.</s><s>Incorrect treatment patterns have been identified, and the high cost of unnecessary investigations and treatments is due to poor compliance with guidelines and best practices.</s><s>Additional analyses should explore these findings in detail.</s><s>To address unmet needs in CSU, it will be important to promote treatment guidelines and evidencebased practices among healthcare providers.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>in the moderate and 33.3 (3.93) in the severe activity groups (Figure 2).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>3. 3 |</head><label>3</label><figDesc><div><p><s>CSU has a major impact on HRQoL, sleep, and daily life</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>( 6 .</head><label>6</label><figDesc><div><p><s>4 [5.55])</s><s>domains of the Urticaria Patient Daily Diary (UPDD) (Figure 3D).</s><s>The Work Productivity and Activity Impairment (WPAI) results substantiated these findings: One-third of patients reported considerable impairments (mean [SD] 32.8% [28.96%]) in daily nonwork activities.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>1</head><label>1</label><figDesc><div><p><s>Study measures.</s><s>AE-QoL=Angioedema Quality of Life Questionnaire; CU-Q 2 oL=Chronic Urticaria Quality of Life Questionnaire; d=days; DLQI=Dermatology Life Quality Index; UAS7=Urticaria Activity Score over 7 days, twice-daily assessment; UPDD=Urticaria Patient Daily Diary; WPAI-SHP=Work Productivity and Activity Impairment-Specific Health Problem (276 of 673) had experienced CSU-associated angioedema within the past 12 months from inclusion.</s><s>According to the patient survey, 65.8% of patients (427 of 649) reported experiencing angioedema during the previous 12 months; of these, 75.2% (321 of 427) reported having experienced angioedema within the past 4 weeks.</s><s>Patients with angioedema reported on a scale of 0-10 the amount of itching (mean [SD] 7.2 [2.16]), swelling (7.3 [2.73]), and pain (5.4 [3.39]) they experienced during a typical episode over the past 12 months.</s><s>When asked what they would typically do when they experienced angioedema, 21.5% of patients reported that they would go to the ED for treatment, 12.9% would take an over-the-counter medication, and 19.9% would do nothing.</s><s>During the 7-day UPDD period, 47.9% of patients (294 of 614) reported at least 1 day of angioedema.</s><s>Occurrence of angioedema increased with disease activity, as more than two-thirds of patients (70.1%) in the UAS7 28-42 band reported experiencing angioedema on at least 1 of 7 consecutive days.</s><s>The mean (SD) number of days with angioedema ranged from 2.3 (1.60) among patients in the UAS7 0-6 band to 4.1 (2.18) days among patients in the UAS7 28-42 band.</s><s>Angioedema significantly affected HRQoL, particularly emotional well-being.</s><s>Mean (SD) Angioedema Quality of Life Questionnaire (AE-QoL) scores were 65.0 (25.14) on the fears/shame domain and 52.1 (25.83) on the fatigue/mood domain among all patients experiencing angioedema; patients with greater CSU activity reported more significant impacts on these domains (Figure 4).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>3 3</head><label>33</label><figDesc><div><p><s>Impact of CSU on HRQoL, sleep, and daily life.</s><s>(A).</s><s>CU-Q 2 oL total and domain scores, overall and by disease activity a,b .</s><s>(B).</s><s>DLQI domain scores, overall and by disease activity c .</s><s>(C).</s><s>Moderate and extreme problems on EQ-5D-3L domains, overall and by disease activity c,d .</s><s>(D).</s><s>Interference with sleep and interference with daily activities, overall and by disease activity c,e .</s><s>CSU=chronic spontaneous urticaria; CU-Q 2 oL=Chronic Urticaria Quality of Life Questionnaire; DLQI=Dermatology Life Quality Index; SD=standard deviation; UAS7=Urticaria Activity Score over 7 d, twice-daily assessment.</s><s>a CU-Q 2 oL results exclude Germany, where the domains differ.</s><s>Results for Germany can be found in Table S4 in Appendix S4. b Ns in legend represents the total number of survey completers in each UAS7 score band.</s><s>Some of these patients had insufficient data to calculate an overall score and/or individual domain scores.</s><s>c Ns in legends represents the total number of survey completers in each UAS7 score band.</s><s>Some of these patients had insufficient data to calculate domain scores.</s><s>d Patterned bars indicate the percentage of patients overall or in each score band with moderate problems, and solid bars indicate the percentage of patients overall in each score band with extreme problems.</s><s>e Weekly score is calculated as the sum of daily sleep or daily interference scores (range of 0 [no interference] to 3 [substantial interference]), divided by the number of nonmissing daily scores, multiplied by 7more comprehensive evidence than is captured using only administrative data sources (e.g., medical claims).</s><s>As both disease activity and HRQoL were evaluated over a similar period, the impact of varying levels of disease activity on patients' lives was clarified.Moreover, we identified significant humanistic and economic burdens relating to CSU that have not been reported previously.</s><s>Nevertheless, estimates of disease burden from this study may beconservative, and the observed treatment patterns might not represent the general CSU population.</s><s>Patients were recruited from urticaria specialty centers and, as such, were receiving expert care for CSU.</s><s>Most patients in ASSURE-CSU had moderate-to-severe physician-assessed disease activity at diagnosis, and patients experienced a mean delay of 24 months (and a median delay of nearly 5 months) from symptom onset to diagnosis; mean duration from diagnosis to enrollment was nearly 5 years.</s><s>Most patients continued to have moderate-to-severe disease activity (ie, moderate-tosevere itch and hives at least 4 days a week) while completing Continued the patient diary.</s><s>However, treatment could be suboptimal and in fact was absent for some patients during the study period.</s><s>Patients not receiving treatment may have discontinued previous treatments owing to ineffectiveness or cost factors, among other reasons.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>7 F</head><label>7</label><figDesc><div><p><s>findings in the United States that 2% of patients with CSU (of any severity) had CSU-related ED visits and 0.1% of patients were hospitalized.</s><s>Differences in national healthcare systems and in CSU severity among the study populations may UAS7: 0-6 (n = 38) UAS7: 7-15 (n = 83) UAS7: 16-27 (n = 107) UAS7: 28-42 (n = 69) Overall: (N = 321) I G U R E 4 AE-QoL domain scores, overall and by disease activity.</s><s>AE-QoL=Angioedema Quality of Life Questionnaire; UAS7=Urticaria Activity Score over 7 d, twice-daily assessment.</s><s>Ns in legend represents the total number of patients in each UAS7 score band who reported angioedema over the past 4 wk in the patient survey.</s><s>Some patients had insufficient data to calculate one or more AE-QoL domain scores contribute to the discrepancy in hospitalization patterns.</s><s>However, Broder and colleagues found a similar number of annual office visits for CSU (3.4 vs 3.3 in ASSURE-CSU).</s><s>Moreover, in ASSURE-CSU, CSU-related out-of-pocket expenses to patients averaged nearly PPP$500 per year and approached PPP$1000 in Canada.</s><s>As patients in our study were still symptomatic despite treatment, many sought alternative medical therapies, which are generally not covered by country health insurances.</s><s>In addition, CSU considerably affected productivity, such that one in five patients took time off from work and one in four experienced reduced productivity at</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>2013 2</head><label>2</label><figDesc><div><p><s>and was approved for inadequately controlled CSU in 2014.</s><s>However, omalizumab had not yet launched in the study countries during data collection, and few patients (&lt;6%) in this study were treated with it.</s><s>Future research should explore how disease burden and outcomes in CSU are affected by the introduction of omalizumab, its inclusion in the clinical guidelines, and its uptake in clinical practice.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>5 F I G U R E 5</head><label>55</label><figDesc><div><p><s>c o r t i c o s t e r o i d s Therapies used in the past 12 mo (N=673).</s><s>LTRA=leukotriene receptor antagonists.</s><s>Other immunosuppressants included methotrexate and mycophenolate mofetil; other specified therapies included intravenous immunoglobulin, narrowband ultraviolet B procedure, dapsone, hydroxychloroquine, levamisole, mesalazine, sulfasalazine, nifedipine, stanozolol, and warfarin.</s><s>Multiple H 1 -antihistamines included combinations of second-and/or third-generation H 1 -antihistamine therapies, as well as patients who have multiple records of the same H 1 -antihistamine</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Chronic Urticaria Quality of Life Questionnaire domains</head><label></label><figDesc></figDesc><table><row><cell>100</cell><cell>100</cell><cell></cell><cell cols="6">Approximately 50% of patients had UAS7 ≥ 16, indicating moderate-to-severe urticaria symptoms</cell><cell>Mean UAS7 score for each disease activity category Overall (N = 548) UAS7: 0-6 (n = 88)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>42</cell><cell>UAS7: 7-15 (n = 178)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>77.9</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>UAS7: 16-27 (n = 151)</cell></row><row><cell cols="2">F I G U R E 2 Urticaria Activity Score over 49.3 Mean ± SD score 22.5 26.6 39.7 33.6</cell><cell>55.2</cell><cell cols="3">UAS7: 7-15 (n = 206) UAS7: 16-27 (n = 182) UAS7: 28-42 (n = 117) 63.9 45.4 36.2 38.3</cell><cell>19.3% 34.0% 30.1% 55.7 25.5 30.5 44.9</cell><cell>35.5</cell><cell>Mean ± SD weekly score 51.2 42.3 28.6 22.9</cell><cell>29.3</cell><cell>21.9 24.0 34.1 39.3</cell><cell>11.2 18.2 20.9 33.4 UAS7: 28-42 (n = 91) 21.5 33.3 15.1 16.5 43.5 34.9 28.0 24.9 21.7</cell></row><row><cell>7 d (UAS7). SD=standard deviation;</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">UAS7=Urticaria Activity Score over 7 d, twice-daily assessment. Note: UAS7 scores 0 0</cell><cell></cell><cell>UAS7: 0-6 (n = 100)</cell><cell></cell><cell></cell><cell>16.5%</cell><cell></cell><cell></cell><cell>3.3</cell></row><row><cell cols="2">twice-daily assessments of hive count and score were assessed by summing the average of Overall</cell><cell></cell><cell>Pruritus</cell><cell>0</cell><cell cols="2">problems Sleep</cell><cell></cell><cell>1 0 0 Looks</cell><cell>0</cell><cell>UAS7: 0-6 Limitations</cell><cell>UAS7: 7-15 life activities UAS7: 16-27 Impact on Swelling UAS7: 28-42</cell></row><row><cell cols="2">itch score and summing these daily scores</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">Percent of</cell><cell></cell><cell>(n = 100)</cell><cell>(n = 206)</cell><cell>(n = 182)</cell><cell>(n = 117)</cell></row><row><cell>over 7 d</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">patients (%)</cell><cell></cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p><s>The authors gratefully acknowledge the following recruiting physicians: Drs.</s><s>Sameh Hanna, Jacques Hebert, Amin Kanani, Paul Keith,</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>SUPPORTING INFORMATION</head><p><s>Additional Supporting Information may be found online in the supporting information tab for this article.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Gina</forename><surname>Lacuesta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jason</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G-Daniel</forename><surname>Schachter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Susan</forename><surname>Waserman</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Shahin Zanganeh in Canada</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m" type="main">Fabien Pelletier, Nadia Rasion-Peyron, Delphine Staumont-Salle, and Manuelle Viguier in France</title>
		<author>
			<persName><forename type="middle">Emmanuelle</forename><surname>Drs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Annick</forename><surname>Amsler-Soria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Claire</forename><surname>Barbaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Laurence</forename><surname>Bernier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jean-Jacques</forename><surname>Bouillet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Giordano</forename><surname>Grob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Laurent</forename><surname>Labadie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Paul</forename><surname>Machet</surname></persName>
		</author>
		<author>
			<persName><surname>Martin</surname></persName>
		</author>
		<editor>Drs. Andrea Bauer, Randolf Brehler, Hans Merk, Franziska Rueff, Petra Staubach-Renz, and Amir Yazdi in Germany</editor>
		<editor>Drs. Ornella de Pit a, Silvia Mariel Ferrucci, Maria Laura Flori, Giampiero Girolomoni, Giovanni Pellacani</editor>
		<imprint/>
	</monogr>
	<note>and Domenico Schiavino in Italy</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">in the United Kingdom. Kate Lothman of RTI Health Solutions provided medical writing services</title>
		<author>
			<persName><surname>Drs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Menno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R R</forename><surname>Gaastra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L A</forename><surname>Kuiters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Schuttelaar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Thomas</forename><surname>Tupker</surname></persName>
		</author>
		<author>
			<persName><surname>Rustemeyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Alejandro Joral Badas</title>
		<editor>Drs. Anthony Bewley, Seautak Cheung, Nyz Chiang, Venkata Gudi, Frances Humphreys, Dimtra Koumaki, John Reed, and Donna Torley</editor>
		<imprint/>
	</monogr>
	<note>Phyllis Spuls, and Roy Gerth van Wijk in the Netherlands. which were funded by Novartis Pharma AG</note>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title level="m" type="main">INTERESTS This research was performed under a research contract between RTI Health Solutions and Novartis Pharma AG and was funded by</title>
		<author>
			<persName><surname>Confli</surname></persName>
		</author>
		<author>
			<persName><surname>Of</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">are employees of RTI Health Solutions, which provides consulting and other research services to pharmaceutical, device, governmental, and nongovernment organizations. In their salaried positions, they work with a variety of companies and organizations. They receive no payment or honoraria directly from these organizations for services rendered</title>
		<author>
			<persName><forename type="first">Novartis</forename><surname>Pharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ag</forename><forename type="middle">K H</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mcb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">was an employee of RTI Health Solutions when this research was conducted. M.M.B. is an employee of Novartis Pharma AG. H.T. is an employee of Novartis Pharmaceuticals Corporation</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title/>
		<author>
			<persName><surname>Author</surname></persName>
		</author>
		<author>
			<persName><surname>Butions</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M B</forename></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mcb</surname></persName>
		</author>
		<editor>M.M.B., K.H., D.McB, C.S., and D.W.</editor>
		<imprint/>
	</monogr>
	<note>designed the study</note>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main">provided clinical input to the study design</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">B</forename></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">O E</forename></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G-A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename></persName>
		</author>
		<author>
			<persName><forename type="first">J-P</forename><forename type="middle">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O D F</forename></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename></persName>
		</author>
		<editor>M.A., F.B., W.C.</editor>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">O E</forename></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G-A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename></persName>
		</author>
		<author>
			<persName><forename type="first">J-P</forename><forename type="middle">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mcb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O D F</forename></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename></persName>
		</author>
		<imprint/>
	</monogr>
	<note>interpreted the data</note>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title level="m" type="main">revised it critically for intellectual content. All authors reviewed and approved the final</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M B</forename></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Mcb ; M</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">B</forename></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">O E</forename></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G-A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename></persName>
		</author>
		<author>
			<persName><forename type="first">J-P</forename><forename type="middle">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O D F</forename></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename></persName>
		</author>
		<imprint/>
	</monogr>
	<note>manuscript and agree to be accountable for the work as a whole</note>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title/>
		<author>
			<persName><surname>R E F E R E N C E S</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Chronic idiopathic urticaria (CIU) is no longer idiopathic: time for an update!</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gimenez-Arnau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brit J Dermatol</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="page" from="455" to="456" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">The EAACI/GA(2) LEN/EDF/ WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Aberer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Asero</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="868" to="887" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients</title>
		<author>
			<persName><forename type="first">E</forename><surname>Toubi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kessel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Avshovich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="869" to="873" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre</title>
		<author>
			<persName><forename type="first">P</forename><surname>Van Der Valk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Moret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kiemeney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">146</biblScope>
			<biblScope unit="page" from="110" to="113" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Epidemiology of urticaria in Spain</title>
		<author>
			<persName><forename type="first">P</forename><surname>Gaig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Olona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Muñoz</forename><surname>Lejarazu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Investig Allergol Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="214" to="220" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">An overview of chronic urticaria</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">S</forename><surname>Beltrani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Rev Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="147" to="169" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria</title>
		<author>
			<persName><forename type="first">M</forename><surname>S Anchez-Borges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Caballero-Fonseca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Capriles-Hulett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gonz Alez-Aveledo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="964" to="971" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Chronic idiopathic urticaria: prevalence and clinical course</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kulthanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jiamton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Thumpimukvatana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pinkaew</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Dermatol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="294" to="301" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Unmet clinical needs in chronic spontaneous urticaria: a GA²LEN task force report</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="317" to="330" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Up-dosing non-sedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Guill En-Aguinaga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Auregui Presa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Aguinaga-Ontoso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Guill En-Grima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ferrer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">175</biblScope>
			<biblScope unit="page" from="1153" to="1165" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Reeves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Boyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bonfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dobson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Loewenthal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Intern Med J</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="182" to="186" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Magerl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Dtsch Dermatol Ges</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="971" to="978" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">The impact of chronic urticaria on the quality of life</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>O'donnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lawlor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Simpson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Greaves</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="197" to="201" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">The impact of chronic idiopathic urticaria on quality of life in Korean patients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">O</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Park</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Dermatol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="226" to="229" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">The impact of chronic urticaria from the patient&apos;s perspective: a survey in five European countries</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Balp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vietri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Isherwood</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Patient</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="551" to="558" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Patient-reported impact of chronic urticaria compared with psoriasis in the United States</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Mendelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Bernstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gabriel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Dermatolog Treat</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="229" to="236" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey</title>
		<author>
			<persName><forename type="first">J</forename><surname>Vietri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Isherwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Balp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gabriel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Allergy Asthma Immunol</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="306" to="311" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria</title>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Grattan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Transl Allergy</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">29</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">)LEN/ EDF/WAO guideline: definition, classification and diagnosis of urticaria</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Asero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="1417" to="1426" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Declaration of Helsinki: ethical principles for medical research involving human subjects</title>
		<ptr target="http://www.wma.net/en/30publications/10policies/b3/17c.pdf.Accessed" />
	</analytic>
	<monogr>
		<title level="j">World Medical Association</title>
		<imprint>
			<date type="published" when="2008-10">October 2008. April 16. 2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title level="m" type="main">EuroQol-a new facility for the measurement of health related quality of life. Health Policy</title>
		<author>
			<persName><forename type="first">Euroqol</forename><surname>Group</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1990">1990</date>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">199</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Khan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="210" to="216" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-Q2oL)</title>
		<author>
			<persName><forename type="first">I</forename><surname>Baiardini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pasquali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Braido</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1073" to="1078" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings</title>
		<author>
			<persName><forename type="first">A</forename><surname>Młynek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Magerl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hanna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="927" to="936" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Development and construct validation of the angioedema quality of life questionnaire</title>
		<author>
			<persName><forename type="first">K</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Groffik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Magerl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="1289" to="1298" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Demonstrating measurement equivalence of the electronic and paper formats of the Urticaria Patient Daily Diary in patients with chronic idiopathic urticaria</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Flood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Zazzali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Devlen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Patient</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="225" to="231" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Development of a daily diary for patients with chronic idiopathic urticaria</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Mathias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Dreskin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Saini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Spector</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ros</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Allergy Asthma Immunol</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="142" to="148" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title level="m" type="main">Work Productivity and Activity Impairment Questionnaire</title>
		<author>
			<persName><forename type="first">M</forename><surname>Reilly</surname></persName>
		</author>
		<ptr target="http://www.reillyassociates.net/Index.html.Accessed" />
		<imprint>
			<date type="published" when="2004-12">2004. December 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria</title>
		<author>
			<persName><forename type="first">D</forename><surname>Stull</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mcbride</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">177</biblScope>
			<biblScope unit="page" from="1093" to="1101" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Urticaria Activity Score (UAS7) and Dermatology Life Quality Index (DLQI) in validation of chronic spontaneous urticaria (CSU/ CIU) health states</title>
		<author>
			<persName><forename type="first">S</forename><surname>Khalil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mcbride</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gimenez-Arnau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Grattan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M-M</forename><surname>Balp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Stull</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page">B131</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<monogr>
		<title level="m" type="main">Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force Report-Part I. Value Health</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Hay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Smeeding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Carroll</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2010">2010</date>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="3" to="7" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">How to calculate indirect costs in economic evaluations</title>
		<author>
			<persName><forename type="first">B</forename><surname>Liljas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacoeconomics</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="7" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>Pt 1</note>
</biblStruct>

<biblStruct xml:id="b45">
	<monogr>
		<title level="m" type="main">PPPs and exchange rates</title>
		<ptr target="https://stats.oecd.org/Index.aspx?DataSetCode=SNA_TABLE4" />
		<imprint>
			<date type="published" when="2014-12-21">2014. December 21. 2015</date>
			<publisher>OECD</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">)LEN/ EDF/WAO guideline: management of urticaria</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zuberbier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Asero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="1427" to="1443" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Translating the science of quality of life into practice: what do dermatology life quality index scores mean?</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Hongbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Harrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Salek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="659" to="664" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Current severe psoriasis and the rule of tens</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="861" to="867" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Resource use and costs in an insured population of patients with chronic idiopathic/ spontaneous urticaria</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Broder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Raimundo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Antonova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Chang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Dermatol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="313" to="321" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Delong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Culler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Saini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="page" from="35" to="39" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Cost effectiveness of levocetirizine in chronic idiopathic urticaria: a pooled analysis of two randomised controlled trials</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kapp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Demarteau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Drug Investig</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey</title>
		<author>
			<persName><forename type="first">J</forename><surname>Whiteley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Emir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Seitzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Makinson</surname></persName>
		</author>
		<idno type="DOI">10.1080/03007995.2016.1195733</idno>
		<ptr target="https://doi.org/10.1080/03007995.2016.1195733" />
	</analytic>
	<monogr>
		<title level="j">Curr Med Res Opin</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Impact of disease severity on work productivity and activity impairment in Japanese patients with atopic dermatitis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Yano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Saeki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ishiji</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Dermatol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="736" to="739" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Schaefer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Cappelleri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cheng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="585" to="593" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Korman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pike</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Roberts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="514" to="521" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Dole zal T, Pet r ıkov a A. Work productivity and costs related to patients with ankylosing spondylitis, rheumatoid arthritis, and psoriasis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kruntor Adov A K, Klime S</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sedov A</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stolfa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Value Health Reg Issues</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="100" to="106" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Epidemiology, healthcare, resources, use and clinical features of different types of urticaria. Alergol ogica</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ferrer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Investig Allergol Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="21" to="26" />
			<date type="published" when="2005">2005. 2009</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">H1-antihistamine-refractory chronic spontaneous urticaria: it&apos;s worse than we thought-first results of the multicenter real-life AWARE study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Staubach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Raap</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Richter-Huhn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bauer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Allergy</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="684" to="692" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
